Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
|Articles|March 1, 2010
- Pharmaceutical Executive-03-01-2010
- Volume 0
- Issue 0
Pharmaceutical Executive Digital Edition - March 2010
Merck’s Man in Emerging Markets
Advertisement
Articles in this issue
over 16 years ago
JWTover 16 years ago
Sixth Annual Press Auditover 16 years ago
Stay Ahead of the Technology Curveover 16 years ago
E-Health to Drive Drug Safetyover 16 years ago
Echo Torre Lazurover 16 years ago
The Race Is Onover 16 years ago
MicroMassover 16 years ago
Saatchi & Saatchiover 16 years ago
Palioover 16 years ago
Moving Beyond Compliant Social MediaAdvertisement
Related to this article
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Pharma logistics are overqualified by design — and how agentic AI can now optimize across thousands of lanes in days, not months.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
ESC 2026: GLP-1–Based Therapies Move Further into Mainstream Cardiovascular Care
4
Before You Sign with a New Hub Vendor, Ask These Four Questions
5